Low complication rate in immunocompromised children with varicella-zoster virus infections in a single centre.
chickenpox
herpes zoster
immunocompromised
outcome
varicella-zoster virus
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
18
05
2019
revised:
30
10
2019
accepted:
29
11
2019
pubmed:
1
12
2019
medline:
15
5
2021
entrez:
1
12
2019
Statut:
ppublish
Résumé
Recent studies focusing on morbidity and mortality rates of immunocompromised children with varicella-zoster virus (VZV) infections are scarce. We aimed to summarise our experience. The study was a retrospective analysis of the medical records of children, who were admitted to Hadassah-Hebrew University Medical Centre, Jerusalem, Israel, during the period of 2008-2016. Data regarding baseline characteristics, treatment and outcome were extracted from patient's medical files. We enrolled 74 patients (43% males) with a mean age of 8 (1-19) years. Most patients (72%) had no reported complications. Clinical outcome was favourable with 73 (99%) patients who had completely recovered and none died. Multivariable analysis identified the presence of fever (P = .005 and 0.02; hazard ratio (HR) 7.72 and 17.61, for total and herpes zoster groups, respectively) and prolonged interval period from clinical presentation to treatment onset (P = .021 and 0.025; HR 1.68 and 2.26, respectively), as associated with higher rates of complications. Our results found low complication rate of VZV-associated infections in immunocompromised children admitted to a single centre. This should encourage conducting further large multicentre studies evaluating management of low-risk patients with oral acyclovir treatment.
Substances chimiques
Acyclovir
X4HES1O11F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1409-1416Informations de copyright
© 2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
Références
Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016.
Cohen JI. Herpes zoster. N Engl J Med. 2013;369:1766-1767.
Law B, MacDonald N, Halperin S, et al. The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J. 2000;19:1053-1059.
Carapetis JR, Russell DM, Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine. 2004;23:755-761.
Sama Ashan JN. Age-specific leukocyte differential. In: Tschudy MM, Arcara KM, eds. The Johns Hopkins Hospital: The Harriet Lane Handbook, 19 ed. Philadelphia, PA: Elsevier; 2012:333.
Leibovitz E, Cooper D, Giurgiutiu D, et al. Varicella-zoster virus infection in Romanian children infected with the human immunodeficiency virus. Pediatrics. 1993;92:838-842.
Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: seventy-seven cases. Pediatrics. 1975;56:388-397.
Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987;80:465-472.
Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018;8:e020528.
Imafuku S, Matsuki T, Mizukami A, et al. Burden of herpes zoster in the Japanese population with immunocompromised/chronic disease conditions: results from a cohort study claims database from 2005-2014. Dermatol Ther (Heidelb). 2019;9:117-133.
Letellier MC, Amini R, Gilca V, Trudeau G, Sauvageau C. Herpes zoster burden in Canadian provinces: a narrative review and comparison with Quebec provincial data. Can J Infect Dis Med Microbiol. 2018;2018:3285327.
Toniolo-Neto J, Psaradellis E, Karellis A, et al. Measuring herpes zoster disease burden in Sao Paulo, Brazil: a clinico-epidemiological single-center study. Clinics (Sao Paulo). 2018;73:e243.
Lu L, Suo L, Li J, Pang X. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. Hum Vaccines Immunother. 2018;14:2632-2635.
Nilsson A. What benefits do immunocompromised children get from the varicella zoster virus vaccination? Acta Paediatr. 2018;107:2046-2047.
Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8:259-270.
Shinjoh M, Takahashi T. Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir. J Hosp Infect. 2009;72:163-168.
Wutzler P, De Clercq E, Wutke K, Farber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol. 1995;46:252-257.